Found 10165 results for

Brands

Alfoo banner

Alfoo- Relief from LUTS-BPH

ALFOO, containing  Alfuzosin molecule, is Anti-BPH which helps in treatment of LUTS due to BPH in Young Sexually Active Male in 40-60 year old age group
Alfoo banner

Alfoo- Relief from LUTS-BPH

ALFOO, containing  Alfuzosin molecule, is Anti-BPH which helps in treatment of LUTS due to BPH in Young Sexually Active Male in 40-60 year old age group
Alfoo banner
button
Alfoo banner

Alfoo- Relief from LUTS-BPH

ALFOO, containing  Alfuzosin molecule, is Anti-BPH which helps in treatment of LUTS due to BPH in Young Sexually Active Male in 40-60 year old age group
button
Video Preview Image

Ketorol-DT 1

Ketorol-DT: Effective NSAID for Acute Dental Pain Relief in Adults (18-60). Discover how Ketorolac Tromethamine in Ketorol-DT provides fast and effective relief from acute dental pain for adults aged 18 to 60.
Video Preview Image

Ketorol-DT 1

Ketorol-DT: Effective NSAID for Acute Dental Pain Relief in Adults (18-60). Discover how Ketorolac Tromethamine in Ketorol-DT provides fast and effective relief from acute dental pain for adults aged 18 to 60.
Video Preview Image
button
Video Preview Image

Ketorol-DT 1

Ketorol-DT: Effective NSAID for Acute Dental Pain Relief in Adults (18-60). Discover how Ketorolac Tromethamine in Ketorol-DT provides fast and effective relief from acute dental pain for adults aged 18 to 60.
button
Video Preview Image

Vono 20-Always on Duty

Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
Video Preview Image

Vono 20-Always on Duty

Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
Video Preview Image
button
Video Preview Image

Vono 20-Always on Duty

Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
button
Video Preview Image

Vono-Always on Duty

Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
Video Preview Image

Vono-Always on Duty

Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
Video Preview Image
button
Video Preview Image

Vono-Always on Duty

Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
button

Webinars

button
button
button
button

Videos

Nephrotic Syndrome And CKD by Dr. C Vasudevan

Discussion about role of DPO in Anemia management

10 Dec 2024
button

Courses

button
button

Medshorts

Orthodontic pain
2Min Read

Laser and Ultrasound Therapies Equally Effective in Reducing Orthodontic Pain, Study Reveals

A randomized controlled trial has demonstrated that both low-level laser therapy (LLLT) and low-intensity pulsed ultrasound (LIPUS) are effective in reducing pain caused by orthodontic separation. 
The study involved 145 patients, divided into three groups: LLLT, LIPUS, and a control group that received no additional intervention beyond separator placement.
Pain intensity was measured using a Visual Analog Scale (VAS) at multiple time points over four days. The LLLT and LIPUS groups received three treatment doses—immediately after separator placement, and at 24 and 48 hours—applied to the maxillary and mandibular first molars. 
Both therapies significantly reduced pain compared to the control group at all assessment points (P < .001). The highest pain levels were reported 24 hours after separator placement, but patients receiving either LLLT or LIPUS experienced considerable relief.
Interestingly, there was no significant difference in pain reduction between the laser and ultrasound groups, indicating that both modalities are equally effective in managing orthodontic pain. 
This study highlights the potential of these non-invasive therapies in improving patient comfort during orthodontic procedures, offering a promising adjunct to standard treatment protocols for pain management without the need for pharmacological intervention.
 

18 Dec 2024
Orthodontic pain

Laser and Ultrasound Therapies Equally Effective in Reducing Orthodontic Pain, Study Reveals

A randomized controlled trial has demonstrated that both low-level laser therapy (LLLT) and low-intensity pulsed ultrasound (LIPUS) are effective in reducing pain caused by orthodontic separation. 
The study involved 145 patients, divided into three groups: LLLT, LIPUS, and a control group that received no additional intervention beyond separator placement.
Pain intensity was measured using a Visual Analog Scale (VAS) at multiple time points over four days. The LLLT and LIPUS groups received three treatment doses—immediately after separator placement, and at 24 and 48 hours—applied to the maxillary and mandibular first molars. 
Both therapies significantly reduced pain compared to the control group at all assessment points (P < .001). The highest pain levels were reported 24 hours after separator placement, but patients receiving either LLLT or LIPUS experienced considerable relief.
Interestingly, there was no significant difference in pain reduction between the laser and ultrasound groups, indicating that both modalities are equally effective in managing orthodontic pain. 
This study highlights the potential of these non-invasive therapies in improving patient comfort during orthodontic procedures, offering a promising adjunct to standard treatment protocols for pain management without the need for pharmacological intervention.
 

Orthodontic pain
button
Orthodontic pain

Laser and Ultrasound Therapies Equally Effective in Reducing Orthodontic Pain, Study Reveals

A randomized controlled trial has demonstrated that both low-level laser therapy (LLLT) and low-intensity pulsed ultrasound (LIPUS) are effective in reducing pain caused by orthodontic separation. 
The study involved 145 patients, divided into three groups: LLLT, LIPUS, and a control group that received no additional intervention beyond separator placement.
Pain intensity was measured using a Visual Analog Scale (VAS) at multiple time points over four days. The LLLT and LIPUS groups received three treatment doses—immediately after separator placement, and at 24 and 48 hours—applied to the maxillary and mandibular first molars. 
Both therapies significantly reduced pain compared to the control group at all assessment points (P < .001). The highest pain levels were reported 24 hours after separator placement, but patients receiving either LLLT or LIPUS experienced considerable relief.
Interestingly, there was no significant difference in pain reduction between the laser and ultrasound groups, indicating that both modalities are equally effective in managing orthodontic pain. 
This study highlights the potential of these non-invasive therapies in improving patient comfort during orthodontic procedures, offering a promising adjunct to standard treatment protocols for pain management without the need for pharmacological intervention.
 

18 Dec 2024
button
Renal-Anemia
2Min Read

Jianpi Shengxue Tablet Improves Iron Metabolism and Nutritional Status in Renal Anemia, reports a Multicenter Clinical Study

This multicenter, randomized, open, parallel-controlled clinical study evaluated the effectiveness of the Jianpi Shengxue tablet in treating renal anemia. 
A total of 200 patients with renal anemia were enrolled between December 2020 and December 2022 and randomly assigned to either a control group treated with a polysaccharide-iron complex or an experimental group receiving Jianpi Shengxue tablets. After 8 weeks of continuous treatment, outcomes related to anemia and iron metabolism were compared between the two groups.
Results indicated that the experimental group showed significant improvements in red blood cell count (RBC), hematocrit (HCT), reticulocyte percentage (RET), serum ferritin (SF), serum iron (SI), transferrin saturation (TSAT), and serum albumin (ALB), while clinical symptom scores and total iron binding capacity decreased (P<0.01). 
Notably, improvements in RBC, HCT, RET, SF, SI, TSAT, ALB, and clinical symptoms such as fatigue, anorexia, dull skin complexion, and numbness were significantly greater in the experimental group compared to the control group (P<0.05). The overall effectiveness rate of Jianpi Shengxue tablets was significantly higher than that of the control treatment (P<0.01).
These findings demonstrate that Jianpi Shengxue tablets are effective in managing renal anemia, significantly enhancing iron metabolism, nutritional status, and clinical symptoms, offering a promising alternative for anemia treatment in patients with kidney disease.
 

16 Dec 2024
Renal-Anemia

Jianpi Shengxue Tablet Improves Iron Metabolism and Nutritional Status in Renal Anemia, reports a Multicenter Clinical Study

This multicenter, randomized, open, parallel-controlled clinical study evaluated the effectiveness of the Jianpi Shengxue tablet in treating renal anemia. 
A total of 200 patients with renal anemia were enrolled between December 2020 and December 2022 and randomly assigned to either a control group treated with a polysaccharide-iron complex or an experimental group receiving Jianpi Shengxue tablets. After 8 weeks of continuous treatment, outcomes related to anemia and iron metabolism were compared between the two groups.
Results indicated that the experimental group showed significant improvements in red blood cell count (RBC), hematocrit (HCT), reticulocyte percentage (RET), serum ferritin (SF), serum iron (SI), transferrin saturation (TSAT), and serum albumin (ALB), while clinical symptom scores and total iron binding capacity decreased (P<0.01). 
Notably, improvements in RBC, HCT, RET, SF, SI, TSAT, ALB, and clinical symptoms such as fatigue, anorexia, dull skin complexion, and numbness were significantly greater in the experimental group compared to the control group (P<0.05). The overall effectiveness rate of Jianpi Shengxue tablets was significantly higher than that of the control treatment (P<0.01).
These findings demonstrate that Jianpi Shengxue tablets are effective in managing renal anemia, significantly enhancing iron metabolism, nutritional status, and clinical symptoms, offering a promising alternative for anemia treatment in patients with kidney disease.
 

Renal-Anemia
button
Renal-Anemia

Jianpi Shengxue Tablet Improves Iron Metabolism and Nutritional Status in Renal Anemia, reports a Multicenter Clinical Study

This multicenter, randomized, open, parallel-controlled clinical study evaluated the effectiveness of the Jianpi Shengxue tablet in treating renal anemia. 
A total of 200 patients with renal anemia were enrolled between December 2020 and December 2022 and randomly assigned to either a control group treated with a polysaccharide-iron complex or an experimental group receiving Jianpi Shengxue tablets. After 8 weeks of continuous treatment, outcomes related to anemia and iron metabolism were compared between the two groups.
Results indicated that the experimental group showed significant improvements in red blood cell count (RBC), hematocrit (HCT), reticulocyte percentage (RET), serum ferritin (SF), serum iron (SI), transferrin saturation (TSAT), and serum albumin (ALB), while clinical symptom scores and total iron binding capacity decreased (P<0.01). 
Notably, improvements in RBC, HCT, RET, SF, SI, TSAT, ALB, and clinical symptoms such as fatigue, anorexia, dull skin complexion, and numbness were significantly greater in the experimental group compared to the control group (P<0.05). The overall effectiveness rate of Jianpi Shengxue tablets was significantly higher than that of the control treatment (P<0.01).
These findings demonstrate that Jianpi Shengxue tablets are effective in managing renal anemia, significantly enhancing iron metabolism, nutritional status, and clinical symptoms, offering a promising alternative for anemia treatment in patients with kidney disease.
 

16 Dec 2024
button
benign prostate
2Min Read

Comparison of low- and high-power thulium laser enucleation for benign prostatic hyperplasia with prostates over 80 g

A recent study demonstrated that low-power YAG VapoEnucleation (ThuVEP) is safe, feasible, and effective, showing results similar to high-power ThuVEP in managing benign prostatic obstruction (BPO). The results of this study were published in the World Journal of Urology.
An analysis was carried out on 80 patients with symptomatic BPO and prostatic enlargement exceeding 80 ml. The patients were randomly split into two groups, each consisting of 40 patients. Group A underwent treatment with low-power ThuVEP, while Group B received high-power ThuVEP. Preoperative and early postoperative evaluations were conducted for all patients, with a follow-up analysis of 12 months. Complications were recorded and categorized based on the modified Clavien classification system.
The average age of patients at the time of surgery was 68 (± 6.1) years. The mean prostate volume was 112 (± 20.1) cc. The groups exhibited no significant variations (p value = 0.457). The average operative time for Group A was 88.4 ± 11.79 minutes, and for Group B it was 93.4 ± 16.34 minutes. Group A had a mean enucleation time of 59.68 ± 7.24 minutes, whereas Group B had a mean enucleation time of 63.13 ± 10.75 minutes. Quality of life (QoL), maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), prostate volume, and postvoiding residual urine (PVR) all showed significant improvement after treatment and were not significantly different between those treated with different energies. Complications were rare and showed no variation between the two groups.
The above study indicates that low-power ThuVEP is safe, feasible, and effective, demonstrating outcomes comparable with high-power ThuVEP in the management of BPO.
 

16 Dec 2024
benign prostate

Comparison of low- and high-power thulium laser enucleation for benign prostatic hyperplasia with prostates over 80 g

A recent study demonstrated that low-power YAG VapoEnucleation (ThuVEP) is safe, feasible, and effective, showing results similar to high-power ThuVEP in managing benign prostatic obstruction (BPO). The results of this study were published in the World Journal of Urology.
An analysis was carried out on 80 patients with symptomatic BPO and prostatic enlargement exceeding 80 ml. The patients were randomly split into two groups, each consisting of 40 patients. Group A underwent treatment with low-power ThuVEP, while Group B received high-power ThuVEP. Preoperative and early postoperative evaluations were conducted for all patients, with a follow-up analysis of 12 months. Complications were recorded and categorized based on the modified Clavien classification system.
The average age of patients at the time of surgery was 68 (± 6.1) years. The mean prostate volume was 112 (± 20.1) cc. The groups exhibited no significant variations (p value = 0.457). The average operative time for Group A was 88.4 ± 11.79 minutes, and for Group B it was 93.4 ± 16.34 minutes. Group A had a mean enucleation time of 59.68 ± 7.24 minutes, whereas Group B had a mean enucleation time of 63.13 ± 10.75 minutes. Quality of life (QoL), maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), prostate volume, and postvoiding residual urine (PVR) all showed significant improvement after treatment and were not significantly different between those treated with different energies. Complications were rare and showed no variation between the two groups.
The above study indicates that low-power ThuVEP is safe, feasible, and effective, demonstrating outcomes comparable with high-power ThuVEP in the management of BPO.
 

benign prostate
button
benign prostate

Comparison of low- and high-power thulium laser enucleation for benign prostatic hyperplasia with prostates over 80 g

A recent study demonstrated that low-power YAG VapoEnucleation (ThuVEP) is safe, feasible, and effective, showing results similar to high-power ThuVEP in managing benign prostatic obstruction (BPO). The results of this study were published in the World Journal of Urology.
An analysis was carried out on 80 patients with symptomatic BPO and prostatic enlargement exceeding 80 ml. The patients were randomly split into two groups, each consisting of 40 patients. Group A underwent treatment with low-power ThuVEP, while Group B received high-power ThuVEP. Preoperative and early postoperative evaluations were conducted for all patients, with a follow-up analysis of 12 months. Complications were recorded and categorized based on the modified Clavien classification system.
The average age of patients at the time of surgery was 68 (± 6.1) years. The mean prostate volume was 112 (± 20.1) cc. The groups exhibited no significant variations (p value = 0.457). The average operative time for Group A was 88.4 ± 11.79 minutes, and for Group B it was 93.4 ± 16.34 minutes. Group A had a mean enucleation time of 59.68 ± 7.24 minutes, whereas Group B had a mean enucleation time of 63.13 ± 10.75 minutes. Quality of life (QoL), maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), prostate volume, and postvoiding residual urine (PVR) all showed significant improvement after treatment and were not significantly different between those treated with different energies. Complications were rare and showed no variation between the two groups.
The above study indicates that low-power ThuVEP is safe, feasible, and effective, demonstrating outcomes comparable with high-power ThuVEP in the management of BPO.
 

16 Dec 2024
button
AR
2Min Read

Probiotic Mixture Reduces Allergic Rhinitis Symptoms in Children, Study Finds

A randomized controlled trial has shown that a probiotic combination of Bifidobacterium longum and Lactobacillus plantarum (NVP-1703) significantly alleviates symptoms of allergic rhinitis (AR) in children. 
The study included children aged 6 to 19 with perennial AR, who were treated with NVP-1703 or a placebo over a 4-week period.
Results indicated that the total nasal symptom score (TNSS) in the NVP-1703 group decreased significantly compared to the placebo group. Symptom relief was observed both in the morning and evening, with notable improvements in nasal symptom duration and quality of life (QoL), particularly in reducing mouth breathing and itchy nose.
 Additionally, the NVP-1703 group showed reduced levels of inflammatory markers, specifically lower ratios of interleukin (IL)-4 and IL-5 to IL-22, which are associated with allergic responses.
No adverse events were reported, confirming the safety of NVP-1703 in children. These findings suggest that probiotics could offer a safe and effective treatment for managing AR in children, potentially improving both symptom control and overall quality of life. The study adds to the growing body of evidence supporting the role of probiotics in treating allergic conditions.
 

13 Dec 2024
AR

Probiotic Mixture Reduces Allergic Rhinitis Symptoms in Children, Study Finds

A randomized controlled trial has shown that a probiotic combination of Bifidobacterium longum and Lactobacillus plantarum (NVP-1703) significantly alleviates symptoms of allergic rhinitis (AR) in children. 
The study included children aged 6 to 19 with perennial AR, who were treated with NVP-1703 or a placebo over a 4-week period.
Results indicated that the total nasal symptom score (TNSS) in the NVP-1703 group decreased significantly compared to the placebo group. Symptom relief was observed both in the morning and evening, with notable improvements in nasal symptom duration and quality of life (QoL), particularly in reducing mouth breathing and itchy nose.
 Additionally, the NVP-1703 group showed reduced levels of inflammatory markers, specifically lower ratios of interleukin (IL)-4 and IL-5 to IL-22, which are associated with allergic responses.
No adverse events were reported, confirming the safety of NVP-1703 in children. These findings suggest that probiotics could offer a safe and effective treatment for managing AR in children, potentially improving both symptom control and overall quality of life. The study adds to the growing body of evidence supporting the role of probiotics in treating allergic conditions.
 

AR
button
AR

Probiotic Mixture Reduces Allergic Rhinitis Symptoms in Children, Study Finds

A randomized controlled trial has shown that a probiotic combination of Bifidobacterium longum and Lactobacillus plantarum (NVP-1703) significantly alleviates symptoms of allergic rhinitis (AR) in children. 
The study included children aged 6 to 19 with perennial AR, who were treated with NVP-1703 or a placebo over a 4-week period.
Results indicated that the total nasal symptom score (TNSS) in the NVP-1703 group decreased significantly compared to the placebo group. Symptom relief was observed both in the morning and evening, with notable improvements in nasal symptom duration and quality of life (QoL), particularly in reducing mouth breathing and itchy nose.
 Additionally, the NVP-1703 group showed reduced levels of inflammatory markers, specifically lower ratios of interleukin (IL)-4 and IL-5 to IL-22, which are associated with allergic responses.
No adverse events were reported, confirming the safety of NVP-1703 in children. These findings suggest that probiotics could offer a safe and effective treatment for managing AR in children, potentially improving both symptom control and overall quality of life. The study adds to the growing body of evidence supporting the role of probiotics in treating allergic conditions.
 

13 Dec 2024
button